Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich

Key Opinion Leaders gather to discuss: LDL-c: Done Deal, Next Epigenetics?

Dr. Ewelina Kulikowski of Resverlogix to present data on the effect of apabetalone on vascular inflammation

CALGARY, Alberta, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announced it is supporting a satellite symposium on August 25^th, 2018, at the European Society of Cardiology Congress 2018 in Munich, Germany, titled: LDL-c: Done Deal, Next Epigenetics?

Satellite Symposium Agenda

15:30 - 15:35 (local time): Introduction
Ulrich Laufs, MD – Leipzig, Germany

15:35 - 15:50: The real residual risk in patients with CVD & diabetes: The promise of epigenetics
Erik Stroes, MD – Amsterdam, Netherlands

15:50 - 16:10: Understanding epigenetics: The potential rationale for BET inhibition in management of CVD
Jorge Plutzky, MD – Boston, USA

16:10 - 16:25: A clinical view on BET inhibition in targeting residual risk in CVD and diabetes
Kausik Ray, MD

16:25 – 16:30: Discussion & summary
Co-Chairmen
Kausik Ray, MD
Ulrich Laufs, MD

Symposium presentations and videos will be posted to the Company website HERE once available.

Satellite Symposium Educational Objectives

• To summarize the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
• To understand the origin of the high residual cardiovascular risk in patients with diabetes and CVD
• To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
• To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

In addition to the satellite symposium, Dr. Ewelina Kulikowski, Senior Vice President of Research & Development of Resverlogix will provide an oral presentation during the Basic and Translational Science Hot Line - Vascular Biology session on Aug. 27, 2018 at 15:00 (local time), titled: Apabetalone (RVX-208) Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and in Inflamed Mouse Aorta.

In Other News

Resverlogix will be participating at the following upcoming conferences:

• 20^th Annual Rodman & Renshaw Global Investment Conference, September 4-6, 2018, New York City
• NewsMakers in the Biotech Industry, September 7^th, 2018, New York City
• BIO Investor Forum, October 17-18, 2018, San Francisco

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, Alzheimer's disease, Fabry disease, and Orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.